1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Venus Medtech (Hangzhou) Inc.
  6. News
  7. Summary
    2500   CNE100003PJ8


Delayed Hong Kong Stock Exchange  -  04:09 2022-08-05 am EDT
15.06 HKD   +4.15%
07/13China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System
07/13Chinese Regulator Approves Venus Medtech's Valve Replacement System
06/22First American Patient Treated with VenusP-Valve™ Under Compassionate Use
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Venus Medtech Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

06/22/2022 | 05:31am EDT

Venus Medtech (Hangzhou) Inc. announced that VenusP-Valve™, an in-house developed novel medical device (2500.HK, hereinafter referred to as "Venus Medtech"), recently completed its first compassionate use at University of Virginia Advanced Cardiac Valve Center in the U.S. The procedure was performed at the Center by Professor Scott Lim's team under on-site guidance from Professor Yuan Feng and remote guidance from Professor Mao Chen, who are both from Cardiology Department, West China Hospital, Sichuan University in China. As the first-ever clinical application of a Chinese-developed heart valve product in the U.S., the case corroborates not only the unique clinical value of VenusP-Valve™ but also the significance of global-oriented innovation. Although there are several transcatheter pulmonic valve replacement (TPVR) products available in the U.S. market, such as Melody™ TPV and Harmony™ TPV by Medtronic and the SAPIEN series by Edwards, they do not work for the considerable number of patients with dilated right ventricular outflow tract (RVOT). As a large-diameter product, VenusP-Valve™ can satisfy the clinical needs of 85% of patients in the case of large RVOT. In May 2022, VenusP-Valve™ was approved by the FDA for compassionate use in two patients. This first patient was a 21-year-old man who suffered from severe pulmonary regurgitation, right ventricular dilation, pulmonary artery dilation, and left ventricular dysfunction after transannular patch (TAP) repair of Tetralogy of Fallot (TOF). The procedure was performed under local anesthesia where the patient remained conscious. Upon preoperative CT, intraoperative contrast-enhanced ultrasound, and balloon measurement, a P34-25 (valve diameter 34mm, straight length 25mm) VenusP-Valve™ that precisely fit the patient's anatomy was delivered through the right femoral vein. On the first postoperative day, ultrasound scan indicated a marked decrease in right ventricle volume with no pulmonary regurgitation. Left ventricular function also returned to normal. Making a sound recovery according to postoperative assessment, the patient was discharged on June 18 (within 24 hours of the procedure) local time. Professor Chen congratulated on the first compassionate use of VenusP-Valve™ in the U.S. As he noted, VenusP-Valve™ has gained broad recognition from the global cardiology community since its first implantation in 2013. In particular, the product is a lifesaver for patients with dilated RVOT. Its transcatheter approach reduces trauma and speeds recovery, enhancing quality of life for patients in various dimensions. In April 2022, VenusP-Valve™ became the first Chinese-developed self-expanding TPVR product to receive CE marking under the Medical Devices Regulation (MDR). Uniquely designed with both flared ends, the product ensures the blood flow of branchial artery with bare stents at the outflow end. It provides a stable multi-point anchoring system and enables easy delivery, with no need for pre-stenting before the procedure. Available in a variety of specifications with extensive applicability, the product is able to meet the needs of 85% of patients. VenusP-Valve™ is also undergoing review and approval with the Chinese National Medical Products Administration (NMPA) and is expected to be marketed within 2022. During its nine-year clinical use since 2013, VenusP-Valve™ has been applied to nearly 300 cases for humanitarian reasons, spanning more than 20 countries and regions in Asia, Europe, North America, and South America. In March 2021, VenusP-Valve™ received special use authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for use in designated medical institutions. VenusP-Valve™ has impressive clinical data backing up its long-term safety and efficacy. According to two-year follow-up result of the clinical study in Europe, the product demonstrated 100% procedural success, with no reoperation or death observed in two years. In addition, moderate and severe pulmonary regurgitation plunged from 16.88% and 83.12% preoperatively to 0%. The data suggest excellent performance, robust safety and reliability, and drastic and steady improvements in patients' cardiac function.

© S&P Capital IQ 2022
07/13China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's..
07/13Chinese Regulator Approves Venus Medtech's Valve Replacement System
06/22First American Patient Treated with VenusP-Valve™ Under Compassionate Use
06/22Venus Medtech Inc. Announces First American Patient Treated with VenusP-Valve Under Com..
04/13Venus Medtech Completes First-in-Human Study of Bioprosthetic Heart Valve Product
04/12Venus Medtech Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Comple..
04/12Venus Medtech Wins Approval to Sell Cardiovascular Device in Europe
03/31VENUS MEDTECH ANNOUNCES 2021 ANNUAL : pacesetter in China and breakthrough-maker worldwid..
03/31Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
03/21Atom Semiconductor announced that it has received $15.8 million in funding from Gobi Pa..
More news
Sales 2022 644 M 95,2 M 95,2 M
Net income 2022 -308 M -45,5 M -45,5 M
Net cash 2022 2 543 M 376 M 376 M
P/E ratio 2022 -20,7x
Yield 2022 -
Capitalization 5 681 M 840 M 840 M
EV / Sales 2022 4,87x
EV / Sales 2023 3,47x
Nbr of Employees 905
Free-Float 79,7%
Duration : Period :
Venus Medtech (Hangzhou) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENUS MEDTECH (HANGZHOU) INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 7
Last Close Price 12,97 CNY
Average target price 21,62 CNY
Spread / Average Target 66,6%
EPS Revisions
Managers and Directors
Zhen Jun Zi Executive Director & General Manager
Hai Yue Ma Chief Financial Officer & Joint Secretary
Min Zeng Chairman
Yan Xiao Chairman-Supervisory Board
Hou-Sen Lim Chief Technology & Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
SMITH & NEPHEW PLC-17.24%11 235
AXONICS, INC.26.79%3 488